Research
Hormonal
Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.
Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.
StrongSupportsmedium confidence
The advent of therapeutic agents with pleiomorphic effects across multiple organ systems, such as glucagon-like peptide-1 receptor agonists, may encourage clinicians to take a more holistic approach to treatment of people with CKM.
Why this rating
The claim is based on the recognition of therapeutic agents' effects.
Source
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
Sonal Kumar et al. · JACC Advances · 2026
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →